LKB1 phosphorylation and deactivation in lung cancer by NNAL, a metabolite of tobacco-specific carcinogen, in an isomer-dependent manner
- 14 July 2022
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 41 (33) , 4042-4054
Abstract
LKB1 loss of function is one key oncogenic event in lung cancer. Clinical data suggest that LKB1 loss of function is associated with patients’ smoking status. The responsible ingredients and molecular mechanisms in tobacco for LKB1 loss of function, however, are not defined. In this study, we reported that NNAL, a major metabolite of a tobacco-specific carcinogen NNK, induces LKB1 phosphorylation and its loss of function via the β-AR/PKA signaling pathway in an isomer-dependent manner in human lung cancer cells. NNAL exposure also resulted in enhanced lung cancer cell migration and chemoresistance in an LKB1-dependent manner. A 120-day NNAL exposure in lung cancer cells, mimicking its chronic exposure among smokers, resulted in more prominent LKB1 phosphorylation, cell migration, and chemoresistance even in the absence of NNAL, indicating the long-lasting LKB1 loss of function although such an effect eventually disappeared after NNAL was removed for two months. These observations were confirmed in a lung cancer xenograft model. More importantly, human lung cancer tissues revealed elevated LKB1 phosphorylation in comparison to the paired normal lung tissues. These results suggest that LKB1 loss of function in human lung cancer could be extended to its phosphorylation, which may be mediated by NNAL from tobacco smoke in an isomer-dependent manner via the β-AR/PKA signaling pathway.Keywords
Funding Information
- National Institute of Health
- National Science Foundation of China
This publication has 55 references indexed in Scilit:
- NNK promotes migration and invasion of lung cancer cells through activation of c-Src/PKCι/FAK loopCancer Letters, 2012
- Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancerOncogene, 2011
- Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in smokers in the united states: NHANES 2007–2008Biomarkers, 2010
- LKB1 and AMP‐activated protein kinase control of mTOR signalling and growthActa Physiologica, 2009
- A Prospectively Measured Serum Biomarker for a Tobacco-Specific Carcinogen and Lung Cancer in SmokersCancer Epidemiology, Biomarkers & Prevention, 2009
- Extensive Metabolic Activation of the Tobacco-Specific Carcinogen 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone in SmokersCancer Epidemiology, Biomarkers & Prevention, 2008
- LKB1 modulates lung cancer differentiation and metastasisNature, 2007
- Prevalence and specificity of LKB1 genetic alterations in lung cancersOncogene, 2007
- Tumorigenicity and metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol enantiomers and metabolites in the A/J mouseCarcinogenesis, 1999
- Metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in the patas monkey: pharmacokinetics and characterization of glucuronide metabolitesCarcinogenesis, 1993